

# EUROPEAN JOURNAL OF NANOMEDICINE

## EDITORS-IN-CHIEF

*Patrick Hunziker*, University Hospital Basel, Switzerland

*Jan Mollenhauer*, University of Southern Denmark, Odense, Denmark

## SCIENTIFIC MANAGING EDITOR

*Georgette B. Salieb-Beugelaar*, University Hospital Basel, Switzerland

## MANAGING EDITOR CLINAM

*Beat Löffler*, European Foundation for Clinical Nanomedicine, Basel, Switzerland

## EDITORS

*Christoph Alexiou*, University Hospital Erlangen, Germany

*Yechezkel Barenholz*, The Hebrew University of Jerusalem, Israel

*Kenneth Dawson*, University College Dublin, Ireland

*Rutledge Ellis-Behnke*, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

*Bengt Fadeel*, Karolinska Institute, Stockholm, Sweden

*Silke Krol*, Neurological Institute Foundation Carlo Besta, Milan, Italy

*Dong Soo Lee*, Seoul National University, Seoul, South Korea

*Claus-Michael Lehr*, Saarland University, Saarbrücken, Germany

*Eder Lilia Romero*, Quilmes National University, Bernal, Buenos Aires, Argentina

*Simó Schwartz*, Vall d'Hebron University Hospital, Barcelona, Spain

*Janos Szebeni*, Semmelweis University, Budapest, Hungary

## EDITORIAL BOARD

*Ghaleb Husseini*, American University of Sharjah, Sharjah, United Arab Emirates

*Harald Mangge*, Medical University of Graz, Graz, Austria

*Bert Müller*, University of Basel, Switzerland

*Dan Peer*, Tel Aviv University, Tel-Aviv, Israel

*Giacinto Scoles*, Princeton University, Princeton, New Jersey, USA

*Patrick W. Serruys*, Erasmus University Medical Center, Rotterdam, The Netherlands

## EDITORIAL ADVISOR

*Lajos Balogh*, AA Nanomedicine & Nanotechnology Consultants, Boston, Massachusetts, USA

## DE GRUYTER

*published in cooperation with CLINAM – European Foundation for Clinical Nanomedicine*

The *European Journal of Nanomedicine (EJNM)* is covered by the following services: Baidu Scholar · Case · Celdes · Chemical Abstracts Service (CAS): CAPlus; SciFinder · CNKI Scholar (China National Knowledge Infrastructure) · CNPIEC · EBSCO (relevant databases) · EBSCO Discovery Service · Elsevier: Compendex; EMBASE; Engineering Village; Reaxys; SCOPUS · Genamics JournalSeek · Google Scholar · J-Gate · JournalTOCs · Meta (formerly Scisearch) · Naviga (Softweco) · Paperbase · Pirabase · Polymer Library · Primo Central (ExLibris) · ProQuest (relevant databases) · ReadCube · ResearchGate · SCImago (SJR) · Sherpa/RoMEO · Summon (Serials Solutions/ProQuest) · TDOne (TDNet) · Thomson Reuters: Emerging Sources Citation Index · Ulrich's Periodicals Directory/ulrichsweb · WorldCat (OCLC)

*EJNM* places emphasis on the clinical application of nanoscience tools, methods and materials and the diverse implications of Nanomedicine. It aims to benefit patients by publishing clinically focused research.

The publisher, together with the authors and editors, has taken great pains to ensure that all information presented in this work (programs, applications, amounts, dosages, etc.) reflects the standard of knowledge at the time of publication. Despite careful manuscript preparation and proof correction, errors can nevertheless occur. Authors, editors and publisher disclaim all responsibility for any errors or omissions or liability for the results obtained from use of the information, or parts thereof, contained in this work.

The citation of registered names, trade names, trademarks, etc. in this work does not imply, even in the absence of a specific statement, that such names are exempt from laws and regulations protecting trademarks etc. and therefore free for general use.

ISSN 1662-5986 · e-ISSN 1662-596X

All information regarding notes for contributors, subscriptions, open access, back volumes and orders is available online at [www.degruyter.com/view/j/ejnm](http://www.degruyter.com/view/j/ejnm)

**RESPONSIBLE EDITORS** Prof. Dr. med. Patrick Hunziker, University Hospital Basel and European Foundation for Clinical Nanomedicine - CLINAM, Basel, CH, Email: [hunziker@clinam.org](mailto:hunziker@clinam.org)

Prof. Dr. Jan Mollenhauer, Board of Trustees, European Foundation for Clinical Nanomedicine (CLINAM), Basel, Switzerland, Email: [janmollenhauer19@gmail.com](mailto:janmollenhauer19@gmail.com)

Dr. med. h.c. Beat Löffler, CEO of the European Foundation for Clinical Nanomedicine - CLINAM, Basel, CH, Email: [loeffler@clinam.org](mailto:loeffler@clinam.org)

**SCIENTIFIC MANAGING EDITOR** Dr. Ing. Georgette B. Salieb-Beugelaar, University Hospital Basel, CH, Email: [beugelaar@swissnano.org](mailto:beugelaar@swissnano.org)

**JOURNAL MANAGER** Alexandra Hinz, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany, Tel.: +49 (0)30 26005-358, Fax: +49 (0)30 26005-184, Email: [Editorial.Nanomedicine@degruyter.com](mailto:Editorial.Nanomedicine@degruyter.com)

**RESPONSIBLE FOR ADVERTISEMENTS** Claudia Neumann, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany. Tel.: +49 (0)30 260 05-226, Fax: +49 (0)30 260 05-325, Email: [anzeigen@degruyter.com](mailto:anzeigen@degruyter.com)

© 2017 Walter de Gruyter GmbH, Berlin/Boston

**TYPESETTING** Compuscript Ltd., Shannon, Ireland

**PRINTING** Franz X. Stickle Druck und Verlag e.K., Ettenheim

Printed in Germany

**COVER ILLUSTRATION** In the recent years, ferromagnetic nanoparticles that are able to heat under an alternating magnetic field have been of considerable interest in the field of nanotechnology. Special attention is being paid to the study of compounds with a spinel  $\text{Fe}_3\text{O}_4$  and perovskite  $(\text{LaSr})\text{MnO}_3$  structure that can be used as hyperthermia inductors for cancer treatment. For practical use, such nanoparticles should be crystalline, not agglomerated, biocompatible and demonstrate both superparamagnetic properties and high heating efficiency. Ferromagnetic  $\text{Fe}_3\text{O}_4$  and  $(\text{LaSr})\text{MnO}_3$  nanoparticles with desired properties can be synthesized by the use of cryochemical and sol-gel technologies. For in vitro studies, the stable magnetic fluids based on synthesized nanoparticles and aqueous agarose solution can be prepared. In the magnetic study, it should be noted that the temperature of the magnetic fluid based on  $\text{Fe}_3\text{O}_4$  nanoparticles increases linearly to the time of the alternating magnetic field exposing, while for  $(\text{La,Sr})\text{MnO}_3$ -based fluid, it stabilizes within a given temperature range. It was shown that the nanoparticles of  $(\text{La,Sr})\text{MnO}_3$ , unlike  $\text{Fe}_3\text{O}_4$ , are characterized by low toxicity, antioxidant activity and ability to influence the cell-virus interaction on a normal cell line (ST-cell line). The possibility of magnetic fluids obtained in this work to generate heat under the alternating magnetic field exposing as well as the lack of side effects allow to consider them as a potential mean for magnetic hyperthermia.

To learn more about this topic please see the article "Synthesis and comparative characteristics of biological activities of  $(\text{La,Sr})\text{MnO}_3$  and  $\text{Fe}_3\text{O}_4$  Nanoparticles" by Shydlovska et al. on pages 33–43 of this issue.

**Information about the copyright holder:** V.I. Vernadsky Institute of General and Inorganic Chemistry, NAS of Ukraine



## Contents

### Editorial

Marco Siccardi, Beat Löffler, Lajos Balogh and Andrew Owen

**Integrated pharmacokinetic modelling for accelerated nanomedicine translation — 1**

### Review

Mustafa Nadhim Owaid and Ibraheem Jaleel Ibraheem

**Mycosynthesis of nanoparticles using edible and medicinal mushrooms — 5**

### Original Articles

Shamsi Darabi and Mohammad Taghi Mohammadi

**Fullerol potentiates the brain antioxidant defense system and decreases  $\gamma$ -glutamyl transpeptidase (GGT) mRNA during cerebral ischemia/reperfusion injury — 25**

Olga Shydlovska, Nadiya Zholobak, Svitlana Dybkova, Sergej Osinsky, Larissa Bubnovskaya, Oleksandr Yelenich, Sergii Solopan and Anatolii Belous

**Synthesis and comparative characteristics of biological activities of (La, Sr)MnO<sub>3</sub> and Fe<sub>3</sub>O<sub>4</sub> nanoparticles — 33**